C22.1: Intrahepatic bile duct carcinoma
C22.1 is a billable, specific ICD-10-CM code for intrahepatic bile duct carcinoma. It is valid for submission on a claim.
Check C22.1 with the rest of the claim: free scrubberExcludes1: never code together
These conditions cannot occur together. Billing both on the same encounter is a denial.
- malignant neoplasm of hepatic duct (C24.0)
Inclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Cholangiocarcinoma
Other codes that can never be billed with C22.1
Their own Excludes1 notes name this code, so the conflict is not listed above.
- C24Malignant neoplasm of other and unspecified parts of biliary tract
Risk adjustment
C22.1 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 20 Lung and Other Severe Cancers1.136 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.
Medicare coverage
C22.1 is named in 63 Medicare coverage policies: 63 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
- A52480Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article
- A53101Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID® Update
Alphabetic index entries that lead here
- Adenocarcinoma›bile duct type
- Cancer›bile duct type liver
- Cholangiocarcinoma›liver
- Cholangiocarcinoma›unspecified site
- Cystadenocarcinoma›bile duct
- Adenocarcinoma›bile duct type›liver
- Adenocarcinoma›bile duct type›unspecified site
- Carcinoma›bile duct›liver
- Carcinoma›bile duct›unspecified site
Code history
Unchanged in every release from FY2024 to FY2027.